Arcadia Biosciences reported a net loss of $8.9 million for the nine months ended September 30, 2026, compared to a $1.0 million loss in the prior year, primarily driven by valuation losses on financing activities. Total revenues increased to $4.16 million for the nine-month period, while the company strengthened its cash position to $2.84 million through various inducement offers and PIPE financing.
Arcadia Biosciences reported third-quarter 2026 financial results, highlighted by a 24% year-over-year increase in total revenues to $1.6 million. The growth was primarily driven by record quarterly sales for the Zola coconut water brand, which benefited from strong summer promotional programs and expanded distribution.
Term
Q3 2026
“The third quarter was very strong for Zola® with revenues growing 24% compared to the same quarter last year, resulting in the highest quarterly sales the brand has ever reported.”
T.J. Schaefer, CEO of Arcadia
“We are extremely excited to begin shipping our newly formulated espresso flavor this month after receiving pre-launch commitments from several of our leading customers.”
Arcadia Biosciences held its 2026 Annual Meeting of Stockholders where shareholders elected Gregory D. Waller as a Class II director and approved the new 2026 Omnibus Equity Incentive Plan. Stockholders also approved a potential reverse stock split at a ratio between 1-for-2 and 1-for-10, to be implemented at the Board's discretion before June 30, 2027, and ratified executive compensation.